 | | Vol. 10.40 – 19 October, 2022 |
| |
|
|
| Investigators reported live virus neutralization titers against WA1, Delta, BA.1, BA.2 and BA.5 variants in serum samples collected from hospitalized patients infected with SARS-COV-2 Delta or Omicron strains.
[Journal of Clinical Investigation] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors investigated receptor recognition of the omicron’s receptor-binding domain, focusing on four of its mutations surrounding two mutational hotspots.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers assessed if serum ocrelizumab concentration measured at time of vaccination could predict the humoral response after SARS-CoV-2 vaccination.
[Annals of Neurology] |
|
|
|
| In the B.1.1.7 lineage, Del69–70 and Del 144 in NTD, A570D and P681H in SD1 and S982A and D1118H in S2 significantly increased viral entry, whereas T716I resulted in a decrease.
[Cellular & Molecular Immunology] |
|
|
|
| Using a surfaceome CRISPR activation screen, the authors identified human LRRC15 as an inhibitory attachment factor for SARS-CoV-2 entry.
[PLoS Biology] |
|
|
|
| Investigators generated a single-cell transcriptome landscape of severe COVID-19 according to the presence of clonal hematopoiesis of indeterminate potential using peripheral blood mononuclear cells.
[Experimental & Molecular Medicine] |
|
|
|
| Researchers analyzed the phenotype and activity of NK cells in the blood of COVID-19 patients using flow cytometry, single-cell RNA-sequencing, and a cytotoxic killing assay.
[Frontiers in Immunology] |
|
|
|
| Investigators estimated SARS-CoV-2 seroprevalence and infection rate among outpatient clinic attendees in Metro Manila prior to the implementation of the national coronavirus disease vaccination program.
[Tropical Medicine and Health] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| The authors investigated whether early intervention in newly diagnosed people with HIV-1 with a monoclonal anti-HIV-1 antibody with a CD4-binding site, 3BNC117, followed by a histone deacetylase inhibitor, romidepsin, shortly after antiretroviral therapy initiation altered the course of HIV-1 infection.
[Nature Medicine] |
|
|
|
| Investigators carried out a retrospective analysis of monkeypox virus-infected crab-eating macaque archival tissue samples from acute and convalescent phases of infection of clade I or clade II monkeypox virus using immunostaining and RNA in situ hybridization.
[Nature Microbiology] |
|
|
|
| T cell–specific deletion of Orai1 did not exacerbate pulmonary inflammation and viral burdens following IAV infection but protected mice from house dust mite–induced allergic airway inflammation.
[Science Advances] |
|
|
|
| Given the significant and ongoing rise of drug-resistant strains of Mycobacterium tuberculosis within the clinical setting, there is an urgent need for the development of new, safe and effective treatments. The development of a drug-like series based on a fused dihydropyrrolidino-pyrimidine scaffold was described.
[Nature Communications] |
|
|
|
| To understand how somatic hypermutations correlate with BG24 neutralization of HIV-1, scientists reported 4.1 Ã… and 3.4 Ã… single-particle cryo-EM structures of two inferred germline BG24 precursors complexed with engineered Env-based immunogens lacking CD4bs N-glycans.
[Nature Communications] |
|
|
|
| Researchers found that NSUN2’s antiviral effect was largely driven by an enhanced type I interferon (IFN) response. The antiviral signaling pathway was dependent on the cytosolic RNA sensor RIG-I but not MDA5.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators evaluated the predictive factors, mechanical insight, and differences of cytokine levels during anti-cancer/immunosuppressive and direct-acting antiviral.
[Scientific Reports] |
|
|
|
| Anti-Dengue Envelope and anti-Zika NS1 IgG antibodies were tested by ELISA in all recruited patients. Associations between pre-morbid seroprevalence for either or both infections and adverse clinical outcomes of the current dengue infection were explored.
[Scientific Reports] |
|
|
|
|
| During the course of HIV-1 infection, the level of this proinflammatory cytokine is increased in different anatomical compartments, particularly in lymphatic tissues, and this elevation is associated with disease progression.
[Reviews in Medical Virology] |
|
|
|
|
| Revive Therapeutics Ltd. announced that it has finalized an amended protocol to the FDA for the Company’s Phase III clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
[Revive Therapeutics Ltd.] |
|
|
|
| The European Medicines Agency has announced its recommendation to approve a dengue vaccine manufactured by Japanese pharmaceutical company Takeda for people four years and older.
[The Scientist] |
|
|
|
|
| December 12 – 13, 2022
Ghent, Belgium |
|
|
|
|
|
| | Vancouver Infectious Diseases Centre – Vancouver, British Columbia, Canada |
|
|
|
| | University of Florida – Gainesville, Florida, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
| | University of Alberta – Edmonton, Alberta, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
